Prostate cancer screening is not

Risk stratify your patient population.

Know his risk. Optimize his health plan.

Current PSA screening recommendations take into account age, ethnicity and family history



When the choice to screen is left to joint-decision-making discussions:

Take a more personalized approach with geneType, 
an integrated risk assessment.

Extend your conversations around
PSA testing with geneType

Risk stratification can enable more informed decision-making discussion about individualized screening strategies.

Tailor risk reduction and screening recommendations for your patients

Whether you are discussing the impact of lifestyle habits on risk of developing prostate cancer, or you are strategizing about PSA screening intervals or liquid biopsy options, geneType opens the door to risk-reduction conversations with your patient.

Clinically Actionable Insights

GeneType reports are structured to make the results easy to interpret and communicate to a patient.

The GeneType for Prostate Cancer report includes:

  • Snapshot of your patient’s 5-year and lifetime-risk scores
  • Interpretation of what their risk scores mean in the context of your local guidelines
  • Polygenic risk score indicating your patient’s “baseline” prostate cancer risk
  • Information about managing prostate cancer risk factors
  • Types of screening and interventions that may be relevant to your patient’s risk category.


The geneType patient 

GeneType for Prostate Cancer is appropriate for: 

  • Men
  • Ages 30-85 years
  • No known hereditary syndrome carriers e.g. BRCA1 or BRCA2
Are you at risk for severe COVID-19?

 GeneType testing is simple

Step 1

Register as a provider; our team will provide clinical education and other resources as needed.

GeneType will send kits to your clinic to have on hand.

Step 2

Discuss geneType with your patient.

Would geneType help them qualify for additional risk reduction strategies?

Step 3

Complete the Test Requisition form, collect a sample from the patient in the saliva tube provided and return both to geneType.

You will have the option to use a paper requisition, or a secure, compliant portal to complete the ordering process.

Step 4

Leave the rest to us.

GeneType will notify you when your patient’s results are ready.

You will have the option to request a consult with a genetic counsellor,  whether to review your patient’s results and/or to follow-up with your patient, as needed.

Do you have questions? We have answers.

If your question is not shown here, please contact us directly.

How old does my patient have to be to use this test?

GeneType for Prostate Cancer is a prostate cancer risk assessment test for men aged 30 years or older.

Does this test incorporate all potential risk factors for prostate cancer?

Cancer is a multifactorial disease and there are many different risk factors. Of these, geneType integrates the most predictive risk factors into the model. Future models may include additional risk factors as the scientific community’s understanding of prostate cancer continues to evolve.

Can I order this test if my patient is a known carrier for a hereditary cancer syndrome (ie. BRCA1 or BRCA2)?

This test is not applicable to men who have a personal history of prostate cancer or who have already been shown to have a cancer mutation, for example in the BRCA1 or BRCA2 gene, or a diagnosis of a genetic syndrome that may be associated with elevated risk of prostate cancer.

Is this test reimbursed by insurance?

No. At this time geneType is a self-pay test. However, your patient may use FSA/HSA to pay for the test.

What’s the difference between geneType and a liquid biopsy?

GeneType is a risk assessment tool to enable you to stratify your patient population.

Liquid biopsies, such as the Galleri test are novel, but pricey screening options.

A risk stratification tool can be used to identify your patients that might benefit from a novel screening tool like this one.

Interested in ordering more than one disease? Order geneType Multi-Test.

See individual disease pages for more information about each test.

The Multi-Risk suite of tests is for adults 40-85 years of age. At maximum, a woman would be eligible for 8 diseases in the panel; a man would be eligible for 7. Starting at age 30, a patient may qualify for geneType's cancer risk assessments only.

*Patient eligibility dependent on personal medical history, age and sex

Blog posts

  1. American Cancer Society Prostate Cancer Screening Recommendations. Available at: Accessed June 2022.
  2. Fenton JJ et al. JAMA. 2018 ;319(18):1914-1931.
  3. NCCN Clinical Practice Guidelines in Oncology.Prostate Cancer Early Detection. Version 1.2022 — February, 2022. Accessed June 2022


Accredited For Compliance With NPAAC Standards And ISO 15189

CLIA Number 99D2023356